["{\n\"step_by_step_thinking\": \"The question asks whether combining antiretroviral agents in a single dosage form enhances the quality of life for HIV/AIDS patients. The relevant documents describe the development of antiretroviral therapies and their limitations, including the emergence of resistant strains. The discovery of dideoxynucleosides as potent inhibitors of HIV replication led to the approval of AZT for treating HIV-infected patients. However, its use is associated with toxicities, particularly bone marrow suppression. Other dideoxynucleosides have shown activity against HIV in early clinical studies, and large-scale, randomized trials are underway. Studies also suggest that blocking HIV binding to CD4 or inhibiting HIV protease may be effective therapeutic approaches. Antisense oligonucleotide therapy is another area being explored. The documents highlight the importance of controlled trials in advancing treatment options for HIV/AIDS patients. Therefore, it can be inferred that combining antiretroviral agents in a single dosage form may enhance quality of life by improving treatment efficacy and reducing toxicities.\",\n\"answer_choice\": \"A\""]